☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
T1D patients
Boehringer Ingelheim and Lilly Report FDA's EMDAC Outcomes for Empagliflozin (2.5mg) as Adjunct to Insulin for T1D Patients
November 14, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.